Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Associations between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer´s Disease, and Type 2 Diabetes Mellitus – A Register-based Study

Author(s): Helena Kullenberg*, Moa Wibom, Maria Kumlin, Thomas Nyström and Marie M. Svedberg

Volume 20, Issue 2, 2023

Published on: 06 June, 2023

Page: [109 - 119] Pages: 11

DOI: 10.2174/1567205020666230522102641

Price: $65

conference banner
Abstract

Background: Metformin, the first-line anti-diabetic drug treatment in patients with type 2 diabetes mellitus (T2DM), is suggested to be anti-inflammatory, antioxidative, and improve cognitive function, making it a promising contribution to treating Alzheimer´s disease (AD). However, the effect of metformin on behavioral and psychological symptoms of dementia (BPSD) in patients with AD has not been explored.

Objective: To investigate the associations between metformin and BPSD in patients with AD and T2DM and explore possible interaction with other antidiabetic drugs.

Methods: This cross-sectional study was based on data from the Swedish BPSD register. A total of 3745 patients with AD and antidiabetic drug treatment were included. Associations and interactions between antidiabetic drugs and BPSD were investigated by binary logistic regression.

Results: The use of metformin was associated with lower odds for symptoms of depression (OR 0.77, CI (95%) 0.61-0.96, p = 0.022) and anxiety (OR 0.74, CI (95%) 0.58-0.94, p = 0.015) after adjustment for age, gender, specific diagnosis, and drugs. We could not demonstrate this association with another antidiabetic drug. Interaction effects were limited to an increasing association in eating and appetite disorders using metformin and other antidiabetic drugs (i.e., drugs other than insulin, sulfonylurea, or dipeptidyl peptidase-4 inhibitors).

Conclusion: The result of this study suggests that metformin could be beneficial for patients diagnosed with AD, other than for blood glucose control. Although, more knowledge is needed before assigning metformin a role in treating BPSD.

Next »
[1]
de la Monte SM. Type 3 diabetes is sporadic Alzheimers disease: Mini-review. Eur Neuropsychopharmacol 2014; 24(12): 1954-60.
[2]
Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-7.
[http://dx.doi.org/10.1038/414782a] [PMID: 11742409]
[3]
Chen W, Cai W, Hoover B, Kahn CR. Insulin action in the brain: Cell types, circuits, and diseases. Trends Neurosci 2022; 45(5): 384-400.
[http://dx.doi.org/10.1016/j.tins.2022.03.001] [PMID: 35361499]
[4]
Zhang J, Chen C, Hua S, et al. An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pract 2017; 124: 41-7.
[http://dx.doi.org/10.1016/j.diabres.2016.10.024] [PMID: 28088029]
[5]
Cummings J, Ortiz A, Castellino J, Kinney J. Diabetes: Risk factor and translational therapeutic implications for Alzheimer’s disease. Eur J Neurosci 2022; 56(9): 5727-57.
[http://dx.doi.org/10.1111/ejn.15619] [PMID: 35128745]
[6]
Pryor R, Cabreiro F. Repurposing metformin: An old drug with new tricks in its binding pockets. Biochem J 2015; 471(3): 307-22.
[http://dx.doi.org/10.1042/BJ20150497] [PMID: 26475449]
[7]
Khezri MR, Yousefi K, Mahboubi N, Hodaei D, Ghasemnejad-Berenji M. Metformin in Alzheimer’s disease: An overview of potential mechanisms, preclinical and clinical findings. Biochem Pharmacol 2022; 197: 114945.
[http://dx.doi.org/10.1016/j.bcp.2022.114945] [PMID: 35134385]
[8]
Zhu X, Shen J, Feng S, et al. Metformin improves cognition of aged mice by promoting cerebral angiogenesis and neurogenesis. Aging 2020; 12(18): 17845-62.
[http://dx.doi.org/10.18632/aging.103693] [PMID: 32938817]
[9]
Lu XY, Huang S, Chen QB, et al. Metformin ameliorates A β pathology by insulin-degrading enzyme in a transgenic mouse model of Alzheimer’s Disease. Oxid Med Cell Longev 2020; 2020: 1-10.
[http://dx.doi.org/10.1155/2020/2315106] [PMID: 32377293]
[10]
Kwon CY, Lee B. Prevalence of behavioral and psychological symptoms of dementia in community-dwelling dementia patients: A systematic review. Front Psychiatry 2021; 12: 741059.
[http://dx.doi.org/10.3389/fpsyt.2021.741059] [PMID: 34744832]
[11]
Makovac E, Serra L, Spanò B, et al. Different patterns of correlation between grey and white matter integrity account for behavioral and psychological symptoms in Alzheimer’s Disease. J Alzheimers Dis 2016; 50(2): 591-604.
[http://dx.doi.org/10.3233/JAD-150612] [PMID: 26836635]
[12]
Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol 2012; 3: 73.
[http://dx.doi.org/10.3389/fneur.2012.00073] [PMID: 22586419]
[13]
Lanari A, Amenta F, Silvestrelli G, Tomassoni D, Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer’s disease. Mech Ageing Dev 2006; 127(2): 158-65.
[http://dx.doi.org/10.1016/j.mad.2005.09.016] [PMID: 16297434]
[14]
Vasilopoulou F, Bagan A, Rodriguez-Arevalo S, Escolano C, Griñán-Ferré C, Pallàs M. Amelioration of BPSD-like phenotype and cognitive decline in SAMP8 mice model accompanied by molecular changes after treatment with I2-imidazoline receptor ligand MCR5. Pharmaceutics 2020; 12(5): 475.
[http://dx.doi.org/10.3390/pharmaceutics12050475] [PMID: 32456135]
[15]
Kales HC, Gitlin LN, Lyketsos CG. When less is more, but still not enough: Why focusing on limiting antipsychotics in people with dementia is the wrong policy imperative. J Am Med Dir Assoc 2019; 20(9): 1074-9.
[http://dx.doi.org/10.1016/j.jamda.2019.05.022] [PMID: 31399358]
[16]
Bränsvik V, Granvik E, Minthon L, Nordström P, Nägga K. Mortality in patients with behavioural and psychological symptoms of dementia: A registry-based study. Aging Ment Health 2020; 1-9.
[PMID: 32067466]
[17]
Dodd S, Sominsky L, Siskind D, et al. The role of metformin as a treatment for neuropsychiatric illness. Eur Neuropsychopharmacol 2022; 64: 32-43.
[18]
Calkin CV, Chengappa KNR, Cairns K, et al. Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD Study). J Clin Psychiatry 2022; 83(2): 21m14022.
[http://dx.doi.org/10.4088/JCP.21m14022] [PMID: 35120288]
[19]
The Swedish BPSD-register BPSD. Available from:https://bpsd.se/(Accessed on: 21-04-28).
[20]
Wood S, Cummings JL, Hsu MA, et al. The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 2000; 8(1): 75-83.
[21]
Wium-Andersen IK, Osler M, Jørgensen MB, Rungby J, Wium-Andersen MK. Diabetes, antidiabetic medications and risk of depression – A population-based cohort and nested case-control study. Psychoneuroendocrinology 2022; 140: 105715.
[http://dx.doi.org/10.1016/j.psyneuen.2022.105715] [PMID: 35338947]
[22]
Lai C. The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders. Clin Interv Aging 2014; 9: 1051-61.
[http://dx.doi.org/10.2147/CIA.S63504] [PMID: 25031530]
[23]
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288(12): 1475-83.
[http://dx.doi.org/10.1001/jama.288.12.1475] [PMID: 12243634]
[24]
Schwertner E, Pereira JB, Xu H, et al. Behavioral and psychological symptoms of dementia in different dementia disorders: A large-scale study of 10,000 individuals. J Alzheimers Dis 2022; 87(3): 1307-18.
[http://dx.doi.org/10.3233/JAD-215198] [PMID: 35491774]
[25]
Pillai JA, Bena J, Rothenberg K, Boron B, Leverenz JB. Association of variation in behavioral symptoms with initial cognitive phenotype in adults with dementia confirmed by neuropathology. JAMA Netw Open 2022; 5(3): e220729.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.0729] [PMID: 35238936]
[26]
Vuic B, Konjevod M, Tudor L, et al. Tailoring the therapeutic interventions for behavioral and psychological symptoms of dementia. Expert Rev Neurother 2022; 22(8): 707-20.
[http://dx.doi.org/10.1080/14737175.2022.2112668] [PMID: 35950234]
[27]
Martocchia A, Scarienzi M, Prunas P, et al. The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer’s disease. F1000 Res 2020; 9: 1470.
[http://dx.doi.org/10.12688/f1000research.26022.1] [PMID: 34316365]
[28]
Cummings J. The neuropsychiatric inventory: Development and applications. J Geriatr Psychiatry Neurol 2020; 33(2): 73-84.
[http://dx.doi.org/10.1177/0891988719882102] [PMID: 32013737]
[29]
Inoue Y, Masuda T, Misumi Y, Ando Y, Ueda M. Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus. Neurosci Lett 2021; 762: 136136.
[http://dx.doi.org/10.1016/j.neulet.2021.136136] [PMID: 34311050]
[30]
Kurochkin IV, Guarnera E, Berezovsky IN. Insulin-degrading enzyme in the fight against Alzheimer’s Disease. Trends Pharmacol Sci 2018; 39(1): 49-58.
[http://dx.doi.org/10.1016/j.tips.2017.10.008] [PMID: 29132916]
[31]
Okura T, Fujioka Y, Nakamura R, et al. Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: A single-arm study, a brief report. Diabetol Metab Syndr 2022; 14(1): 78.
[http://dx.doi.org/10.1186/s13098-022-00850-9] [PMID: 35672759]
[32]
Sola D, Rossi L, Schianca GPC, et al. State of the art paper Sulfonylureas and their use in clinical practice. Arch Med Sci 2015; 4(4): 840-8.
[http://dx.doi.org/10.5114/aoms.2015.53304] [PMID: 26322096]
[33]
Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63(7): 1187-92.
[http://dx.doi.org/10.1212/01.WNL.0000140292.04932.87] [PMID: 15477536]
[34]
Secnik J, Xu H, Schwertner E, et al. The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia. Alzheimers Res Ther 2021; 13(1): 197.
[http://dx.doi.org/10.1186/s13195-021-00934-0] [PMID: 34857046]
[35]
Eissa N, Sadeq A, Sasse A, Sadek B. Role of neuroinflammation in autism spectrum disorder and the emergence of brain histaminergic system. lessons also for BPSD? Front Pharmacol 2020; 11: 886.
[http://dx.doi.org/10.3389/fphar.2020.00886] [PMID: 32612529]
[36]
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 2008; 9(1): 46-56.
[http://dx.doi.org/10.1038/nrn2297] [PMID: 18073775]
[37]
Theofilis P, Sagris M, Oikonomou E, et al. The anti-inflammatory effect of novel antidiabetic agents. Life 2022; 12(11): 1829.
[http://dx.doi.org/10.3390/life12111829] [PMID: 36362984]
[38]
Avogaro A, Delgado E, Lingvay I. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev 2018; 34(4): e2981.
[http://dx.doi.org/10.1002/dmrr.2981] [PMID: 29320602]
[39]
Sluggett JK, Koponen M, Bell JS, et al. Metformin and risk of Alzheimer’s Disease among community-dwelling people with diabetes: A national case-control study. J Clin Endocrinol Metab 2020; 105(4): e963-72.
[http://dx.doi.org/10.1210/clinem/dgz234] [PMID: 31778170]
[40]
López-Rubio C, Koponen M, Lampela P, et al. Changes in the use of diabetes drugs among community-dwelling people with Alzheimer’s disease. BMC Geriatr 2021; 21(1): 701.
[http://dx.doi.org/10.1186/s12877-021-02694-w] [PMID: 34911481]
[41]
Kosjerina V, Carstensen B, Jørgensen ME, et al. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study. Lancet Healthy Longev 2021; 2(9): e561-70.
[http://dx.doi.org/10.1016/S2666-7568(21)00170-7] [PMID: 36098008]
[42]
SFS 2008:355. Patient Data Law [Patientdatalagen]. Available from: https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/patientdatalag-2008355_sfs-2008-355(Accessed on: 22-12-15.).
[43]
Ludvigsson J, Nørgaard M, Weiderpass E, et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol 2015; 7: 491-508.
[http://dx.doi.org/10.2147/CLEP.S90589] [PMID: 26648756]
[44]
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects In: JAMA.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy